VIPER Diagnostics Program Launched to Validate Long COVID Diagnostic Tests and Potential Cures
PolyBio's VIPER Diagnostics Program launches as the first phase of its Long COVID Cure Initiative, aiming to validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID. The program will provide a path to more targeted treatments.
The VIPER Diagnostics Program has launched as part of PolyBio's Long COVID Cure Initiative, aiming to validate diagnostic tests for SARS-CoV-2 persistence and other drivers of Long COVID, paving the way for more targeted treatments. The program will focus on identifying patients with persistent infection or underlying conditions contributing to Long COVID. This milestone marks the first phase of PolyBio's initiative to combat the long-term effects of COVID-19. The ultimate goal is to develop a comprehensive treatment plan for those affected by Long COVID.
